GlassScriptPhysician profile
Robyn Carlisle
NPI 1407026719
$4,172.74
in general payments reported to CMS, 2019-2025
26 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $884 · 2022: $708 · 2023: $640 · 2024: $906 · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,580.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,200.91 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $369.00 | 2021-2024 | Xifaxan, Plenvu |
| Aimmune Therapeutics, INC. | $364.52 | 2024-2025 | Zenpep, Vowst |
| Phathom Pharmaceuticals, INC. | $357.28 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $296.28 | 2021-2023 | |
| Janssen Biotech, INC. | $251.24 | 2023-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $197.42 | 2021-2025 | Entyvio, Eohilia |
| Novo Nordisk INC | $148.46 | 2025 | Wegovy |
| Celgene Corporation | $138.62 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $137.66 | 2021-2025 | Linzess |
| Intercept Pharmaceuticals, INC. | $91.28 | 2023-2025 | Ocaliva |
| Vivus LLC | $80.29 | 2021-2024 | Qsymia |
| E.R. Squibb & Sons, L.L.C. | $75.20 | 2022 | |
| Ardelyx, INC. | $62.68 | 2025 | Ibsrela |
| Genzyme Corporation | $52.48 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $52.12 | 2022-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $44.91 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $37.46 | 2025 | Iqirvo |
| Organon LLC | $36.51 | 2023-2025 | Hadlima |
| Ferring Pharmaceuticals INC. | $31.43 | 2023-2025 | Cimzia, Rebyota |
| Enterra Medical, INC. | $31.04 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.88 | 2023 | Cyltezo |
| Lilly USA, LLC | $27.75 | 2024 | Omvoh |
| Braintree Laboratories, INC. | $23.32 | 2021 | |
| Exact Sciences Corporation | $19.61 | 2024 | Cologuard Collection Kit |
| Lucid Diagnostics INC. | $15.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Carlisle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.